Search Browse Earnings

Enliven Therapeutics, Inc. — SlamSEC

Enliven Therapeutics, Inc.

Nasdaq:ELVN

Pharmaceutical Preparations·BOULDER, CO

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

-$104.3M

FY 2025

Net Income

-$89.0M

FY 2025

EPS (Diluted)

-$1.89

FY 2025

Stock Price

$30.24

+2.7%

2026-03-10

52W Range

$13.30 – $30.63

P/E Ratio

-16.0x

Market Cap

$1.8B

Cash

$124.1M

FY 2025

Total Debt

—

Net Cash

$124.1M

Enterprise Value

$1.7B

Debt / EBITDA

1.2x

FY 2025

EV / EBITDA

-16.2x

Employees

—